FDMT4D Molecular TherapeuticsSigning up patients
Single Intravitreal (IVT) Injection of 4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular Degeneration
Neovascular Age-Related Macular Degeneration (nAMD)
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 3
- Patients
- 480 (planned)
- Started
- Jul 22, 2025
- Main results expected
- Nov 2027
- Fully finished
- Nov 2029
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Mean change from baseline in Best Corrected Visual Acuity (BCVA) Early Treatment for Diabetic Retinopathy (ETDRS) letter score at Week 52
Measured over: 52 Weeks
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT07064759 · record last updated 2026-10-19 · checked 2026-11-09 15:47 UTC